Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IGMS IGM Biosciences	$1.33 +7.3%	$1.22	$0.92 ▼ $22.50	$74.12M	0.61	312,543 shs	567,804 shs
STRO Sutro Biopharma	$0.90 -1.7%	$0.79	$0.52 ▼ $5.17	$76.02M	1.77	1.10 million shs	616,771 shs
VYNE VYNE Therapeutics	$0.97 -1.0%	$1.46	$0.96 ▼ $4.30	$14.68M	1.76	113,137 shs	115,734 shs
ZURA Zura Bio	$1.02 +2.0%	$1.22	$0.97 ▼ $5.56	$69.74M	0.05	414,179 shs	550,887 shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IGMS IGM Biosciences	+7.26%	+10.83%	+1.53%	-2.21%	-85.37%
STRO Sutro Biopharma	-1.71%	-0.29%	+2.89%	-43.40%	-78.82%
VYNE VYNE Therapeutics	-1.03%	-3.50%	-31.56%	-61.71%	-61.86%
ZURA Zura Bio	+2.27%	-1.92%	-26.62%	-25.00%	-79.92%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IGMS IGM Biosciences	4.0074 of 5 stars	3.0	1.0	4.6	2.1	3.3	1.3
STRO Sutro Biopharma	4.2357 of 5 stars	4.1	2.0	4.7	2.1	1.7	0.6
VYNE VYNE Therapeutics	2.7623 of 5 stars	3.5	3.0	0.0	3.3	1.7	0.6
ZURA Zura Bio	2.3568 of 5 stars	3.6	1.0	0.0	2.7	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IGMS IGM Biosciences	1.90	Reduce	$5.50	313.53% Upside
STRO Sutro Biopharma	2.13	Hold	$6.11	579.37% Upside
VYNE VYNE Therapeutics	3.00	Buy	$6.25	547.67% Upside
ZURA Zura Bio	3.13	Buy	$14.33	1,305.23% Upside

Current Analyst Ratings Breakdown

Latest VYNE, STRO, IGMS, and ZURA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/19/2025	STRO Sutro Biopharma	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underperform ➝ Underperform	$1.00 ➝ $0.80
5/9/2025	ZURA Zura Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$19.00 ➝ $17.00
4/29/2025	STRO Sutro Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$2.00 ➝ $2.00
4/25/2025	VYNE VYNE Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.75 ➝ $4.50
4/3/2025	ZURA Zura Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/3/2025	ZURA Zura Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $3.00
3/26/2025	ZURA Zura Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$20.00 ➝ $19.00
3/26/2025	ZURA Zura Bio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
3/26/2025	ZURA Zura Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
3/17/2025	STRO Sutro Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$12.00 ➝ $2.00
3/14/2025	STRO Sutro Biopharma	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$2.00

(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IGMS IGM Biosciences	$2.68M	29.65	N/A	N/A	$3.46 per share	0.38
STRO Sutro Biopharma	$66.43M	1.14	N/A	N/A	$2.45 per share	0.37
VYNE VYNE Therapeutics	$605K	24.26	N/A	N/A	$6.36 per share	0.15
ZURA Zura Bio	N/A	N/A	N/A	N/A	$1.85 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IGMS IGM Biosciences	-$246.42M	-$3.27	N/A	N/A	N/A	-7,534.03%	-155.42%	-61.04%	8/13/2025 (Estimated)
STRO Sutro Biopharma	-$106.79M	-$2.98	N/A	N/A	N/A	-77.01%	-101.89%	-28.69%	8/12/2025 (Estimated)
VYNE VYNE Therapeutics	-$28.45M	-$0.99	N/A	N/A	N/A	-6,896.55%	-43.73%	-38.55%	8/13/2025 (Estimated)
ZURA Zura Bio	-$69.24M	-$0.70	N/A	N/A	N/A	N/A	-37.36%	-29.81%	8/12/2025 (Estimated)

Latest VYNE, STRO, IGMS, and ZURA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	IGMS IGM Biosciences	-$0.41	-$0.86	-$0.45	-$0.86	$4.25 million	$0.50 million
5/8/2025	Q1 2025	STRO Sutro Biopharma	-$0.63	-$0.91	-$0.28	-$0.91	$11.61 million	$17.40 million
5/8/2025	Q1 2025	VYNE VYNE Therapeutics	-$0.29	-$0.20	+$0.09	-$0.20	$0.05 million	$0.20 million
5/8/2025	Q1 2025	ZURA Zura Bio	-$0.17	-$0.19	-$0.02	-$0.19	N/A	N/A
3/25/2025	Q4 2024	ZURA Zura Bio	-$0.17	-$0.08	+$0.09	-$0.08	N/A	$0.00 million
3/13/2025	Q4 2024	STRO Sutro Biopharma	-$0.86	-$2.96	-$2.10	-$0.89	$10.44 million	$14.00 million
3/6/2025	Q4 2024	IGMS IGM Biosciences	-$0.74	-$0.61	+$0.13	-$0.61	$0.39 million	$0.41 million
3/6/2025	Q4 2024	VYNE VYNE Therapeutics	-$0.31	-$0.28	+$0.03	-$0.28	$0.14 million	$0.08 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IGMS IGM Biosciences	N/A	N/A	N/A	N/A	N/A
STRO Sutro Biopharma	N/A	N/A	N/A	N/A	N/A
VYNE VYNE Therapeutics	N/A	N/A	N/A	N/A	N/A
ZURA Zura Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IGMS IGM Biosciences	N/A	5.22	5.22
STRO Sutro Biopharma	N/A	3.09	3.09
VYNE VYNE Therapeutics	N/A	5.81	5.81
ZURA Zura Bio	N/A	10.36	10.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IGMS IGM Biosciences	42.79%
STRO Sutro Biopharma	96.99%
VYNE VYNE Therapeutics	83.78%
ZURA Zura Bio	61.14%

Insider Ownership

Company	Insider Ownership
IGMS IGM Biosciences	57.00%
STRO Sutro Biopharma	3.60%
VYNE VYNE Therapeutics	4.80%
ZURA Zura Bio	14.23%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IGMS IGM Biosciences	190	59.78 million	25.57 million	Optionable
STRO Sutro Biopharma	240	84.46 million	77.59 million	Optionable
VYNE VYNE Therapeutics	30	15.21 million	14.04 million	Not Optionable
ZURA Zura Bio	3	68.38 million	50.86 million	Optionable

VYNE, STRO, IGMS, and ZURA Headlines

Recent News About These Companies

Zura Bio Limited (NASDAQ:ZURA) Receives $14.33 Average Target Price from Analysts

May 27 at 1:17 AM | americanbankingnews.com

Zura Bio Limited (NASDAQ:ZURA) Given Average Recommendation of "Buy" by Brokerages

May 26, 2025 | marketbeat.com

Zura Bio shareholders approve board nominees and auditor

May 24, 2025 | investing.com

HC Wainwright Issues Positive Estimate for Zura Bio Earnings

May 23, 2025 | marketbeat.com

What is HC Wainwright's Forecast for Zura Bio Q2 Earnings?

May 23, 2025 | americanbankingnews.com

Q1 Earnings Estimate for Zura Bio Issued By HC Wainwright

May 22, 2025 | marketbeat.com

Zura Bio commences Phase II trial of tibulizumab for hidradenitis suppurativa

May 21, 2025 | msn.com

What is HC Wainwright's Forecast for Zura Bio Q1 Earnings?

May 21, 2025 | americanbankingnews.com

Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa

May 20, 2025 | businesswire.com

Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates

May 9, 2025 | standard-journal.com

Boxer Capital Management LLC Makes New Investment in Zura Bio Limited (NASDAQ:ZURA)

May 4, 2025 | marketbeat.com

Zura Bio (ZURA) Projected to Post Quarterly Earnings on Thursday

May 3, 2025 | marketbeat.com

Adage Capital Partners GP L.L.C. Buys Shares of 300,000 Zura Bio Limited (NASDAQ:ZURA)

May 2, 2025 | marketbeat.com

Zura Bio Limited (NASDAQ:ZURA) Receives Average Recommendation of "Buy" from Analysts

May 1, 2025 | marketbeat.com

Zura Bio Limited (NASDAQ:ZURA) Short Interest Down 51.8% in April

April 30, 2025 | marketbeat.com

After losing 56% in the past year, Zura Bio Limited (NASDAQ:ZURA) institutional owners must be relieved by the recent gain

April 24, 2025 | finance.yahoo.com

Zura Bio price target lowered to $3 from $5 at H.C. Wainwright

April 4, 2025 | markets.businessinsider.com

Zura Bio (ZURA) Gets a Buy from Guggenheim

March 31, 2025 | markets.businessinsider.com

Hopeful Week For Insiders Who Bought US$1.01m Of Zura Bio Stock

March 26, 2025 | finance.yahoo.com

Zura Bio Limited: 2024 Financial Results and Strategic Progress

March 26, 2025 | tipranks.com

Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates

March 25, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

D-Wave Pushes Back on Short Seller Case With Strong Earnings
By Nathan Reiff | May 14, 2025
View D-Wave Pushes Back on Short Seller Case With Strong Earnings
Palantir’s Latest Deal Could Put a Freeze on Its Stock Price
By Chris Markoch | May 12, 2025
View Palantir’s Latest Deal Could Put a Freeze on Its Stock Price
If the U.S.-China Trade Reset Holds, These 3 Stocks Could Fly
By Chris Markoch | May 16, 2025
View If the U.S.-China Trade Reset Holds, These 3 Stocks Could Fly
Archer Rebuts Short Seller, Points to Strong Q1 & Global Momentum
By Jeffrey Neal Johnson | May 22, 2025
View Archer Rebuts Short Seller, Points to Strong Q1 & Global Momentum
After Earnings Beats, These 3 Stocks Are on Analysts’ Radars
By Leo Miller | May 20, 2025
View After Earnings Beats, These 3 Stocks Are on Analysts’ Radars

VYNE, STRO, IGMS, and ZURA Company Descriptions

IGM Biosciences NASDAQ:IGMS

$1.33 +0.09 (+7.26%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$1.33 0.00 (0.00%)

As of 05/29/2025 06:12 PM Eastern

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Sutro Biopharma NASDAQ:STRO

$0.90 -0.02 (-1.71%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$0.92 +0.02 (+2.33%)

As of 05/29/2025 07:16 PM Eastern

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

VYNE Therapeutics NASDAQ:VYNE

$0.96 -0.01 (-1.03%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$0.99 +0.03 (+2.80%)

As of 05/29/2025 07:29 PM Eastern

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

Zura Bio NASDAQ:ZURA

$1.02 +0.02 (+2.00%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$1.06 +0.04 (+3.92%)

As of 05/29/2025 07:47 PM Eastern

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time